-
公开(公告)号:US20240360522A1
公开(公告)日:2024-10-31
申请号:US18287776
申请日:2022-04-21
发明人: Bassel Ghaddar , Subhajyoti De
IPC分类号: C12Q1/689 , C12Q1/6886 , C12Q1/6895
CPC分类号: C12Q1/689 , C12Q1/6886 , C12Q1/6895 , C12Q2600/118 , C12Q2600/158
摘要: Disclosed herein are systems and methods for identifying biomarkers. Biomarker identification can be achieved while increasing efficiency and decreasing data and computation complexity but maintaining accuracy. Such biomarker identification can be achieved via analysis of differential gene expression, such as determined using single cell RNA-sequencing data sets.
-
公开(公告)号:US20240360517A1
公开(公告)日:2024-10-31
申请号:US18411722
申请日:2024-01-12
IPC分类号: C12Q1/6886 , G06N3/00 , G16B5/00
CPC分类号: C12Q1/6886 , G06N3/00 , G16B5/00 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158
摘要: The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of progression of cancer in a subject. The invention also provides biomarkers that define subgroups of prostate cancer, clinically useful classifiers for distinguishing prostate cancer subtypes, bioinformatic methods for determining clinically useful classifiers, and methods of use of each of the foregoing. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of subtyping prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in subtyping prostate cancer in a subject. Classifiers for subtyping a prostate cancer are provided. Methods of treating cancer based on molecular subtyping are also provided.
-
公开(公告)号:US20240360108A1
公开(公告)日:2024-10-31
申请号:US18581307
申请日:2024-02-19
发明人: Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC分类号: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC分类号: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
摘要: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号:US20240358708A1
公开(公告)日:2024-10-31
申请号:US18649357
申请日:2024-04-29
申请人: Thomas DIACOVO
发明人: Thomas DIACOVO
IPC分类号: A61K31/52 , A61K31/573 , A61K31/713 , C12N9/12 , C12N15/113 , C12Q1/6886 , G01N33/50 , G01N33/573
CPC分类号: A61K31/52 , A61K31/573 , A61K31/713 , C12N9/1205 , C12N15/1137 , C12Q1/6886 , C12Y207/01137 , C12Y207/01153 , G01N33/5041 , G01N33/573
摘要: The present invention provides, inter alia, methods for treating, preventing, or ameliorating the effects of a lymphoid malignancy, such as those associated with a mutated phosphatase and tensin homolog (PTEN) gene, or T-cell acute lymphoblastic leukemia (T-ALL). These methods include administering to a subject an effective amount of a phosphoinositide 3-kinase-delta (PI3Kδ) inhibitor and a phosphoinositide 3-kinase-gamma (PI3Kγ) inhibitor. The present invention also provides pharmaceutical compositions for treating the effects of a lymphoid malignancy. This invention further provides a method for identifying a subject who may benefit from co-treatment with a PI3Kδ inhibitor and a PI3Kγ inhibitor. This method includes determining from a sample of the subject whether the subject has a mutated PTEN gene. Additionally, this invention provides methods for identifying a compound that has both PI3Kδ and PI3Kγ inhibitory activity.
-
公开(公告)号:US12131802B2
公开(公告)日:2024-10-29
申请号:US15443102
申请日:2017-02-27
IPC分类号: G16B20/00 , B01L3/00 , C12Q1/6886 , G01N33/543 , G01N33/574 , G01N33/68 , G16B40/00 , G16H10/40 , G16H50/20 , G16H50/30
CPC分类号: G16B20/00 , B01L3/502 , B01L3/502715 , B01L3/502761 , C12Q1/6886 , G01N33/54366 , G01N33/57434 , G01N33/6893 , G16B40/00 , G16H10/40 , G16H50/20 , G16H50/30 , B01L2300/0654 , B01L2300/0816 , B01L2300/087 , B01L2400/0487 , C12Q2600/112 , C12Q2600/158 , C12Q2600/16 , G01N2333/96455
摘要: Methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided. More particularly, this disclosure relates to methods and apparatuses for providing the models and employing the models for predicting risk of prostate cancer and/or predicting prostate gland volume. The methods and apparatuses for predicting risk of prostate cancer and/or prostate gland volume are provided using, at least in part, information from a panel of kallikrein markers.
-
公开(公告)号:US20240352534A1
公开(公告)日:2024-10-24
申请号:US18644335
申请日:2024-04-24
发明人: David A. Ahlquist , William R. Taylor , Douglas W. Mahoney , Graham P. Lidgard , Hatim T. Allawi
IPC分类号: C12Q1/6886
CPC分类号: C12Q1/6886 , C12Q2600/112 , C12Q2600/154
摘要: Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as colorectal cancer.
-
公开(公告)号:US20240352531A1
公开(公告)日:2024-10-24
申请号:US18432678
申请日:2024-02-05
发明人: Heng MEI , Chenggong LI , Fen ZHOU , Yun KANG
IPC分类号: C12Q1/6886
CPC分类号: C12Q1/6886 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/166
摘要: The present invention belongs to the technical field of molecular biology, and specifically relates to the technical field of efficacy monitoring of a chimeric antigen receptor (CAR)-T cell therapy. The present invention provides use of a primer combination in the preparation of a product for detecting a prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor, where the primer combination includes primers shown in Table 1. The present invention provides use of a primer combination in the preparation of a product for detecting an expression state of CD19 on a surface of a tumor cell in a tumor patient, where the primer combination includes primers shown in Table 1. The present invention provides a product for detecting a prognostic effect of an anti-CD19 CAR-T cell therapy in a tumor, where the product includes primers shown in Table 1 as effective components.
-
公开(公告)号:US20240352449A1
公开(公告)日:2024-10-24
申请号:US18589331
申请日:2024-02-27
发明人: Ariel JAIMOVICH , Sven Jeffrey DUENWALD , Peter Vilem GRAUMAN , Yupeng HE , Charbel Said EID , Haley Dara AXELROD
IPC分类号: C12N15/10 , C12Q1/6886
CPC分类号: C12N15/1065 , C12Q1/6886 , C12Q2600/154 , C12Q2600/156
摘要: Disclosed herein are methods for isolating DNA, such as cell-free DNA (cfDNA) or DNA from a tissue sample, e.g., in which the DNA is partitioned into hypermethylated and hypomethylated partitions. After differential tagging of the partitions, portions of the hypomethylated partition are pooled with the hypermethylated partition or pooled separately. Epigenetic and sequence-variable target regions are captured from the pool comprising DNA from the hypermethylated and hypomethylated partitions, and sequence-variable target regions are captured from the pool comprising DNA from the hypomethylated partition. This approach can reduce costs and/or bandwidth by limiting sequencing of epigenetic target regions from the hypomethylated partition, which may be less informative than other DNA.
-
公开(公告)号:US12123057B2
公开(公告)日:2024-10-22
申请号:US16950825
申请日:2020-11-17
IPC分类号: C12Q1/6883 , C12Q1/6886
CPC分类号: C12Q1/6883 , C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要: The present application provides an in vitro method for determining the degradation of the extracellular matrix (ECM) in a subject, the method comprising determining in an isolated sample from the subject the level of an expression product of at least one gene selected from the group consisting of collagen type V alpha 1 chain (COL5A1), transforming growth factor beta-1 (TGFB1), integrin subunit alpha 4 (ITGA4), integrin subunit beta 1 (ITGB1), matrix metallopeptidase 2 (MMP2), matrix metallopeptidase 9 (MMP9) and bone morphogenetic protein 1 (BMP1), the at least one gene being determined optionally in combination with one or both of collagen type XI alpha 1 chain (COL11A1) and collagen type V alpha 2 chain (COL5A2), wherein when the level of the expression product(s) is(are) higher than a reference value this is indicative of a degraded ECM. Methods for the diagnosis and prognosis of cancer and aneurysms are also provided. Furthermore, means for determining the level of expression product of the genes in the above diagnosis or prognosis methods are also provided, as well as kits containing said means.
-
公开(公告)号:US20240345016A1
公开(公告)日:2024-10-17
申请号:US18683145
申请日:2024-01-29
申请人: ASIMA HEALTH INC.
发明人: Shalini GUPTA , Puja PRASAD , Tejal DUBE , Shantanu CHOWDHURY , Meenakshi VERMA , Ankita SINGH
IPC分类号: G01N27/327 , C12Q1/6886 , G01N27/02
CPC分类号: G01N27/3275 , C12Q1/6886 , G01N27/026
摘要: The present disclosure provides impedance-based detection of nucleic acids for screening of cancer. The present disclosure is based on the use of impedance spectroscopy to detect nucleic acids in solution in the clinical concentration range, without using any labels, amplification steps, bioreceptors, surface modification or complex electrode geometries. More particularly, the present disclosure leverages the structural variations in nucleic acids of healthy and cancer patients, to classify samples as cancer-positive or cancer-negative purely based on their electrophysiochemical properties. The present disclosure also provides a simple rapid, label-free miniaturized biosensor for detection and screening of cancer.
-
-
-
-
-
-
-
-
-